Optiray (Ioversol)

Ioversol contains a high concentration of iodine atoms that absorb X‑ray photons. When injected intravenously, it temporarily raises the radiodensity of blood vessels and extracellular spaces, creating a clear distinction between tissues on X‑ray‑based imaging modalities. This contrast effect fades as the agent is redistributed and eliminated by the kidneys.

The dose of Optiray is individualized and determined by the prescribing clinician based on the specific imaging study, patient size, and renal function. No standard dosing information is provided here; healthcare professionals should follow the product labeling and clinical guidelines when calculating the appropriate volume.

The safety of Optiray in pregnancy and lactation has not been definitively established, and the product carries an unknown pregnancy category. Clinicians should weigh the potential diagnostic benefit against possible fetal or infant risk and consider alternative imaging strategies when possible.

To order Optiray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if required), and any necessary import documentation.

Optiray (ioversol) is a non‑ionic, low‑osmolality iodinated contrast medium, similar to agents such as iohexol or iopamidol. Compared with older high‑osmolality agents, Optiray generally offers a lower incidence of discomfort and adverse reactions while providing comparable image quality. Choice among agents often depends on specific patient factors, institutional protocols, and cost considerations.

Optiray should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture, and freezing. Before use, inspect the vial for particulate matter or discoloration, and allow the product to reach room temperature if it has been stored in a cooler environment.

Optiray is administered as an intravenous injection or infusion, typically through a peripheral or central venous line. The injection rate is determined by the imaging protocol and patient tolerance, with rapid bolus injection often used for CT angiography and slower infusion for other studies. Administration should be performed by qualified healthcare personnel.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute renal impairment, and cardiovascular events like arrhythmias or hypotensive shock. Patients with known iodine allergy, severe renal dysfunction, or unstable cardiac status require careful assessment and monitoring before receiving Optiray.

Optiray should be avoided in individuals with a documented severe hypersensitivity to iodinated contrast media, those with uncontrolled severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m²), and patients who have experienced prior anaphylactic reactions to similar agents. Caution is also advised for patients with uncontrolled thyroid disease or recent use of nephrotoxic medications.